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Abstract
Ribosomopathies are a family of inherited disorders caused by mutations in genes neces-
sary for ribosomal function. Shwachman-Diamond Bodian Syndrome (SDS) is an autoso-
mal recessive disease caused, in most patients, by mutations of the SBDS gene. SBDS is
a protein required for the maturation of 60S ribosomes. SDS patients present exocrine
pancreatic insufficiency, neutropenia, chronic infections, and skeletal abnormalities.
Later in life, patients are prone to myelodisplastic syndrome and acute myeloid leukemia
(AML). It is unknown why patients develop AML and which cellular alterations are directly
due to the loss of the SBDS protein. Here we derived mouse embryonic fibroblast lines
from an SbdsR126T/R126T mouse model. After their immortalization, we reconstituted them
by adding wild type Sbds. We then performed a comprehensive analysis of cellular func-
tions including colony formation, translational and transcriptional RNA-seq, stress and
drug sensitivity. We show that: 1. Mutant Sbds causes a reduction in cellular clonogenic
capability and oncogene-induced transformation. 2. Mutant Sbds causes a marked
increase in immature 60S subunits, limited impact on mRNA specific initiation of transla-
tion, but reduced global protein synthesis capability. 3. Chronic loss of SBDS activity
leads to a rewiring of gene expression with reduced ribosomal capability, but increased
lysosomal and catabolic activity. 4. Consistently with the gene signature, we found that
SBDS loss causes a reduction in ATP and lactate levels, and increased susceptibility to
DNA damage. Combining our data, we conclude that a cell-specific fragile phenotype
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occurs when SBDS protein drops below a threshold level, and propose a new interpreta-
tion of the disease.
Author Summary
Shwachman Diamond syndrome (SDS) is an inherited disease. SDS presents, as hall-
marks, exocrine pancreatic insufficiency, increased rate of infections, and higher inci-
dence of leukemia. Most cases are due to mutations in the SBDS gene. SBDS encodes for a
ribosome maturation factor. In this study, we immortalized mouse fibroblasts carrying
one of the most common mutation of SDS patients and performed a thorough analysis of
their properties. We show that the loss of SBDS activity causes a rewiring of gene expres-
sion and cellular metabolism. Overall we find a reduction of protein synthesis capability, a
lower energy status, and increased lysosomal capability. SBDS mutant cells have an
increased susceptibility to various forms of stress, but are strikingly resistant to oncogene-
induced transformation. We propose a model that explains the complex phenotype of
SDS patients and suggests roads for a rationale treatment.
Introduction
Ribosomopathies are inherited diseases due to the haploinsufficiency of ribosomal proteins or
ribosome processing factors [1, 2]. Patients affected by ribosomopathies present multiorgan
phenotypes [2]. Some relatively common features are bone marrow and skeletal deficits, and
cancer predisposition [3, 4]. At the cellular level, ribosomal haploinsufficiency may cause the
induction of tumor suppressor p53 [2, 5]. Consequently, in some models the depletion of p53
reduces the deleterious effects of ribosomal haploinsufficiency [6–9] leading to the hypothesis
that abnormal p53 is the pathogenic culprit. However, this is not true for all cases [10, 11].
Shwachman-Diamond Syndrome (SDS) is a recessive ribosomopathy affecting 1 in 76,000
births. SDS is a multisystem disorder presenting in the first year of life and characterized by
the hallmark of exocrine pancreatic dysfunction. Another common symptom is the suscepti-
bility to chronic infections accompanied by neutropenia [12, 13]. With variable penetrance,
patients affected by SDS may have low stature, skeletal defects and cognitive impairment [14,
15]. Finally, high risk of acute myeloid leukemia (AML) is associated with older patients [16].
Loss-of-function mutations in the SBDS gene have been identified as the cause of the disease
[17].
Several studies addressed the function of SBDS protein in mammals and of its yeast homo-
log. A concise survey will be presented. SBDS has a role in the maturation of 60S ribosomal
subunits. Deletion of the yeast homolog sdo1 is quasi-lethal, leading to pre-60S nuclear export
defects. Importantly, point mutations of tif6, a gene necessary for 60S biogenesis [18], revert
the quasi-lethal phenotype [19]. These and other studies, have led to a general model in which
SBDS is necessary for the maturation of 60S subunits, in order to remove eIF6 (mammalian
Tif6) from mature 60S subunits [20–22]. Since eIF6 controls 60S availability [23] and full
translational activation [24, 25], manipulation of the binding of eIF6 to the 60S may be critical
for restoring SBDS-mutant cells. A recent report suggested that SBDS contributes to the effi-
cient translation of C/EBPα and C/EBP-β mRNAs, uORF-containing mRNAs that are, among
others, indispensable regulators of granulocytic differentiation [26]. A general analysis of
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translated mRNAs depending from SBDS is still lacking. We do not know in detail whether
other steps of 60S maturation beside eIF6 release are affected.
Several studies have attempted to pinpoint other functions of the SBDS protein, in the obvi-
ous effort to explain the multiorgan phenotype of patients. At the cellular level, several pheno-
types associated to SBDS loss have been described. These phenotypes have been largely
observed either in primary cells from patients, or upon shRNA experiments in cell lines.
Increased apoptosis driven by FAS was seen in HeLa upon SBDS shRNA [27], and increased
ROS production [28]. Increased apoptosis was also seen in SBDS-depleted HEK293 cells upon
DNA and chemically induced endoplasmic reticulum stress [29], and in hemopoietic cells
[30]. SBDS association with mitotic spindle has been proposed [31] and the lack of SBDS has
been associated with genetic instability [32]. In general, reduced clonogenic potential is
observed in hematopoietic precursors upon SBDS depletion [9, 33]. Reduced respiratory capa-
bility has been observed in mammalian and yeast cells lacking SBDS or its homolog, Sdo1p
[34, 35]. Overall, it is unclear whether the cellular phenotypes ascribed to the loss of SBDS
activity are direct or indirect, general or cell-specific, and have a relationship with protein
synthesis.
Recently, a mouse strain in which one of the most frequent missense mutation found in
SDS patients is modeled, R126T, has been produced [36]. This mouse model reproduces the
clinical symptoms of SDS patients. We exploited the availability of this model to address the
cell autonomous effects due to hypomorphic SBDS alleles. We have derived from these mice
embryonic fibroblast cell lines, we have reconstituted control MEFs with wild type SBDS and
then performed a full characterization of their properties. We addressed in SBDS mutant cells
their predisposition to oncogenic transformation, changes in eIF6 binding, transcriptional and
translational changes, metabolic parameters, and sensitivity to drugs and stresses. We unveiled
several features due to the loss of SBDS. We provide a pathogenic model of SBDS deficiency
that focuses on a diminished anabolic and energetic status of Sbds mutant cells due to reduced
protein synthesis, which may be useful to design rational therapeutic ameliorative strategies.
Results
Sbds mutant cells are resistant to oncogene induced transformation
Swhachman-Diamond (SDS) patients have an higher incidence of blood tumors, mainly acute
myeloid leukemia (AML) [37]. This observation raises the question whether SBDS mutant
cells are intrinsically susceptible to oncogene-mediated transformation. SBDS point mutation
R126T corresponds to a common mutation found in SDS patients (c.377G>C) and it has been
modeled in mice [36]. We immortalized R126T mouse embryonic fibroblasts (MEFs), together
with their matched wild type controls, and we evaluated their capability to form colonies. Two
strategies can be employed for immortalization of MEFs, a) sequential subcloning [38] or b)
immortalization and transformation with oncogenes and tumor suppressor inhibitors [39]. By
sequential subcloning, we were unable to derive SbdsR126T/R126T MEFs due to early senescence
(Fig 1A), whereas we normally derived wt cells. This result is in line with a recent work
describing early senescence in the pancreas of SBDS mutants [8]. In contrast, immortalization
of SbdsR126T/R126T MEFs by infection with a vector carrying the dominant negative p53 and Ras
G12V was successful (Fig 1A; S1A and S1B Fig). The growth of immortalized SbdsR126T/R126T
MEFs was virtually identical to the one of wt cells (S1C Fig). Transformation of immortalized
cells is induced by long-term growth at confluency. Next, we analyzed the capability of immor-
talized SbdsR126T/R126T MEF cells to form transformed colonies respect to wild type cells, upon
long term culture at 100% confluency. We observed that SbdsR126T/R126T MEFs formed less foci
respect to the wild type cells (Fig 1B and 1C). We then plated wt MEFs and SbdsR126T/R126T
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MEFs in soft agar, another indicator of transformation efficiency, to test their capability to
grow in anchorage independent condition. We found that surviving clones of SbdsR126T/R126T
MEFs grew as well as wt cells (Fig 1D), but their overall number was lower than the one of wt
MEFs (Fig 1E). In order to evaluate the capability of these transformed colonies to induce
tumor in vivo, we injected 500.000 transformed cells in nude mice and monitored tumor mass
Fig 1. Cells with SbdsR126T/R126T mutation show facilitated senescence, have reduced clonogenic
potential, are refractory to oncogene induced transformation and generate tumor cells with poor
growth in vivo. (A) Scheme of the strategy for immortalization from E12.5 MEFs from SbdsR126T/R126T or wild
type mice and summary data relative to SbdsR126T/R126T cells. (B-C) Generation of immortalized colonies by
infection of E12.5 MEFs at early passages with a retrovirus carrying DNp53 + H-rasV12. SbdsR126T/R126T have
low clonogenic potential. n = 3 per genotype). (B) representaive plates; (C) quantitation (D-E) Soft agar assay
for transformed cells unveils that some SbdsR126T/R126T transformants grow as well as wt (D), but overall they
produce less colonies (E). Scale bar 25 μm. (F) In vivo tumor growth underscores an unexpected incapability
of SbdsR126T/R126T transformants to propagate tumors in mice. Kaplan-Meier curves of CD1 nude mice
subcutaneously injected with SbdsR126T/R126T and wild type MEFs (n = 7 per genotype): death time point is
defined at 400mm3 tumor volume, when mice were euthanized. Number of colonies expressed as mean ± s.d.
Statistic applied for (B-E) was t-test, paired, two-tailed (*P value0.05, ***P0.001). Log-rank (Mantel-Cox)
Test (***P0.0001) was applied to (F).
doi:10.1371/journal.pgen.1006552.g001
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growth. Surprisingly and strikingly (Fig 1F), formally transformed SbdsR126T/R126T cells were
inefficient (n = 1) or unable (n = 6) to grow in vivo respect to the wild type cells. We demon-
strate that SBDS deficiency induces in a cell-autonomous fashion a growth and clonogenic def-
icit that can be unveiled when cells are challenged by environmental conditions.
The primary effect of Sbds hypomorphism is an impairment in translation
capability due to less mature 60S subunits
We established a further model for studying SBDS function by generating, from immortalized
SbdsR126T/R126T MEFs, new clones retransduced with either wild type Sbds (SbdsRESCUE) or
mock control (SbdsMOCK) vectors (S1D Fig). By comparing parental SbdsR126T/R126T clones to
their wild type counterparts, and the SbdsMOCK with the SbdsRESCUE clones, we can discrimi-
nate direct events due to SBDS lack from indirect effects. We describe the most important
observations and discuss later a model that explains the pathogenic effect of SBDS deficiency.
Since SBDS deficiency leads to a ribosomal defect [19], we performed a complete analysis of
translation. Polysomal profiles can be used to analyze defects in initiation as well as in ribo-
some maturation. We observed, in line with previous reports [20], a strong unbalance in 60S
and 80S peaks in SbdsR126T/R126T MEFs respect to the wild type cells (Fig 2A). SbdsRESCUE cells
showed a complete rescue of the profile (Fig 2B), confirming a direct action of SBDS on ribo-
some maturation, and validating our model for discriminating direct versus clonal or indirect
effects. We analyzed rRNA precursors with a pulse-chase assay by monitoring the incorpo-
ration of 5,6 3H-uridine in the nascent ribosomal RNA (S2A Fig). We did not observe differ-
ences in rRNA maturation associated with the SBDS mutation, a result consistent with the
idea that only the late maturation of 60S is affected by SBDS deficiency. The nucleolus is the
nuclear compartment where both ribosome biogenesis and early maturation occur. A defect in
ribosomal export can be assessed by measuring the number and the size of nucleoli. We did
not observe differences in the number of nucleoli between SbdsR126T/R126T and wild type cells
(Fig 2C) or in SbdsMOCK and SbdsRESCUE cells (Fig 2D). In addition, we did not observe differ-
ences in co-localization of SBDS and nucleolar marker nucleophosmin (NPM) between
SbdsR126T/R126T and wild type cells (Fig 2E and 2F). eIF6 nucleolar localization was relatively
similar in SbdsR126T/R126T and wild type cells (S2B Fig).
eIF6 binds 60S subunits, blocking 80S formation and increasing free 60S peak [24]. It has
been proposed that SBDS deficiency blocks eIF6 release [20]. This model is consistent with the
accumulation of free 60S that we observed (Fig 2A). We recently developed a Ribosomes Inter-
action Assay (Fig 2G), able to quantify eIF6 binding sites on the 60S [40]. We immobilized
equal ribosomes from SbdsR126T/R126T and wild type cells, and measured eIF6 binding sites. We
found a 25% reduction in eIF6 binding sites on the ribosomes of SbdsR126T/R126T, compared to
wild type cells (Fig 2H). Thus, we conclude that SBDS deficiency leads to a late maturation def-
icit of 60S consistent with the generation of a reduced pool of functional 60S subunits. It is
worth to note that 60S peak increases at least 2-fold (Fig 2A and 2B), whereas eIF6 binding
sites drop only 25% (Fig 2H).
We asked the consequences of the maturation deficit on translation. We developed a fully
reconstituted in vitro model, in which translation competent extracts are prepared from equal
amount of cells, normalized to the number of ribosomes and transduced with defined amounts
of exogenous mRNA. This experiment allows to measure the maximal translational capability
per cell/per ribosome. Ribosomal extracts from SbdsR126T/R126T MEF showed around 70%
reduction in the translational capability of a cap-dependent reporter (Fig 3A). Cells rescued
with SBDS in vivo (SbdsRESCUE) recovered their translational capability (Fig 3B). Importantly,
adding wild type SBDS in vitro did not rescue the translational capability of extracts prepared
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from SbdsR126T/R126T MEFs (S2C Fig). This result indicates an overall translational impairment.
Next, we adapted the canonical SUnSET protocol to citofluorimetry analysis. We observed
both in SbdsR126T/R126T MEFs respect to wild type (Fig 3C) and in SbdsMOCK MEFs compared
to SbdsRESCUE MEFs (Fig 3D) about 10% reduction in the number of cells incorporating
Fig 2. SBDS deficiency reduces the maximal translational capability up to 70% due to a defect in 60S
maturation that is partly associated with a change in eIF6–free 60S subunits. (A-B) Polysome profiles.
SbdsR126T/R126T cells show an increase in free 60S and lower 80S peaks on sucrose gradient compared to wt
(A). The phenotype is completely restored in SbdsRESCUE cells (B). Note, the increase of free 60S is two-fold.
A254 nm was measured after 15–50% sucrose gradient sedimentation. Representative experiment of n5.
(C-D) Nucleoli analysis. SbdsR126T/R126T (C) and SbdsMOCK cells (D) do not have differences in the number
of nucleoli respect to their control cell lines (wild type and SbdsRESCUE). Distribution of cells containing less or
more of six nucleoli per nucleus in wild type, SbdsR126T/R126T, SbdsRESCUE and SbdsMOCK cells was counted
with Volocity Sofwtare, by analyzing cells stained for the nucleolar marker nucleophosmin (NPM) (n200,
n = number of nuclei analyzed per genotype). (E-F) SBDS and NPM localization. Confocal images wild type
and SbdsR126T/R126T cells indicate a co-localization of SBDS and NPM proteins within the nucleolus, and a
cytoplasmic SBDS. There are no visible differences among all genotypes. Scale bar 25 μm (E) and 2 μm (F).
(G-H) Measurement of eIF6 binding sites by iRIA technique shows that wt cells have 25% more free 60S as
detected by eIF6 binding. (G) iRIA technique outline: SbdsR126T/R126T and wild type cellular extracts were
immobilized on a 96 well and biotinylated eIF6 is added. This assay is able to detect the binding between eIF6
and 60S. (H) SbdsR126T/R126T fibroblasts have less binding sites for eIF6, respect to wild type cell line, i.e. 0.12
arbitrary units versus 0.16. Representative technical triplicate experiment of n4 biological replicates.
doi:10.1371/journal.pgen.1006552.g002
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medium to high levels of puromycin. Taken together, our results demonstrate that R126T
mutation leads to a strong reduction of the pool of 60S subunits competent for translation.
SBDS deficiency causes limited changes in the translation of specific
mRNAs but leads to snoRNAs’ accumulation on immature 60S
An obvious question is whether the impaired maturation of 60S ribosomes, associated with a
reduced translational capability in SbdsR126T/R126T cells, results in a qualitative difference of
translation. We decided to proceed with an RNASeq study on total RNA extracted from
sucrose gradient collected fractions. We studied 1) RNAs associated to polysomes, 2) RNAs
associated to the 80S and 3) steady-state mRNA levels (total RNA) (Fig 4). The isolated frac-
tions are shown in Fig 4A and 4B. The combination of these parameters allowed us to define
the overall translational and transcriptional status associated with SbdsR126T/R126T mutation,
assuming that mRNAs differentially localized to either polysomes or 80S are controlled at
the translational level. We have decided to use this strategy over ribosome profiling because
a) altered 60S subunits may lead to abnormal RNA protection, b) the big change in the 80S
monosomal peak found in SbdsR126T/R126T cells is difficult to be normalized, and c) to effi-
ciently reach deepness of more than 2x107 reads. S1 File contains read counts of polysomes
and total RNAs. S2 File contains read counts of 80S. By comparing the polysomes of
SbdsRESCUE and SbdsMOCK, we identified 844 modulated genes (Fig 4C; S1 File), most of them
enriched in presence of mutant SBDS. However, when we estimated the translational effi-
ciency, i.e. bona fide polysomal enrichment, by normalizing each mRNA level on the poly-
some to the amount present on the total, we found only 74 mRNAs with a significant
modulation. Of these 74, 31 had less than 10 normalized read counts average expression, sug-
gesting that fluctuations of poorly expressed mRNAs may contribute to the observed effects.
The analysis of translation efficiency of SbdsRESCUE and SbdsMOCK confirmed that they do not
differ in qualitative translational regulation (Fig 4D). The analysis on RNAs enriched on 80S
subunits unveiled 250 genes modulated in 80S SbdsMOCK compared to 80S from SbdsRESCUE
Fig 3. SBDS deficiency results in less translation capability. (A-B) In Vitro Translation Assay shows a 2-
to 3-fold impairment in translation of SBDS-mutant extracts. Equal amounts of translation competent extracts
prepared from indicated cells programmed with equal amounts of capped mRNAs. All graphs represent
mean ± s.d. Statistic applied was T-test, paired, two-tailed, n4. (C-D) SUnSET single cell assay indicates a
reduction in the number of cells incorporating mid-high puromycin both in SbdsR126T/R126T (C) and in
SbdsMOCK fibroblasts (D) respect to their controls. Negative cells are low-expressing cells. Graphs represent
mean ± s.d. Statistic applied was T-test, paired, two-tailed, n3.
doi:10.1371/journal.pgen.1006552.g003
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cells (Fig 4E; S2 File). However, identical to what we observed in the polysomal fraction, also
in this case the mRNAs modulation on 80S followed the steady state levels (S3A and S3B Fig)
as well the polysomal. Taken together, the data suggest that SBDS loss induces a solid tran-
scriptional rewiring due to a general impairment of translation rather than specific transla-
tional regulation.
By analyzing polysomal versus steady state mRNAs and 80S modulated in Sbds mutated
cells we made two major observations: a) a 4-fold enrichment of snoRNAs ACA8 and ACA31
Fig 4. RNASeq of 80S and polysome associated RNAs shows that SBDS mutation causes limited
changes in mRNAs associated to polysomes, accumulation of ACA8 and ACA31 snoRNAs on
immature ribosomes. (A-B) Sucrose gradient separations for RNA extraction and RNAseq. In (A) RNA was
extracted from polysomes (fractions corresponding to polysomes were collected in one polysome fraction)
and from the whole gradient (100 μL from each fraction of the gradient were pulled in one total fraction). In (B)
RNA was extracted from 80S and total (not graphed). Colored rectangles correspond to extracted fractions.
(C-D) Translational analysis. SbdsMOCK cells show 844 genes differently expressed genes on polysome
fraction, most of them upregulated respect to the SbdsRESCUE polysome fraction (C), but relative
normalization to total (D) indicates that there is not a consistent change in the specific translational efficiency
of individual mRNAs. (C) Volcano plot representing the differential expression analysis for polysome fraction.
Results obtained comparing SbdsMOCK versus SbdsRESCUE conditions are reported for the pool of tested
genes as -Log10 false discovery rate / Log2 moderate fold change. Genes selected as significantly changed
(FDR < 5%, absolute Log2 fold-change value > 1) are shown in red. (D) Histogram showing the translational
efficiency, calculated as delta Log2 fold-change (Polysome/Total) between SbdsMOCK and SbdsRESCUE. The
normal distribution indicates that very few genes are specifically regulated in the polysomal fraction, once
calculated the Polysome/Total ratio. (E) Volcano plot representing the results of the differential expression
analysis for the 80S fraction. (F) Sequencing unveils accumulation on ribosomes of SbdsMOCK versus
SbdsRESCUE of some snoRNAs.
doi:10.1371/journal.pgen.1006552.g004
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in the ribosomes of SbdsMOCK cells compared to SbdsRESCUE. ACA8 and ACA31 drive the pseu-
douridylation of 28S rRNA U3832 and U3713 on the 60S. Other snoRNAs were not changed
(Fig 4F; S1 and S2 Files). Intriguingly, there was no overlap between the genes regulated at the
polysomal level by Sbds mutation (S1 File), to the ones we previously found regulated by eIF6
deficiency [41].
In conclusion, our data (Figs 2G, 2H, 3 and 4) suggest that the lack of mature 60S leads to a
general reduction of translational capability associated with transcriptional rewiring.
The loss of functional SBDS causes an alteration in the transcriptome
that indicates reduced synthetic and energetic capability but increased
lysosome trafficking and altered proteostasis
The limited specific translational changes seen at the polysomal level (Fig 4), and the strong
reduction in the maximal translational capability (Fig 3) were mirrored by a complex rewiring
of gene expression and metabolism of SBDS deficient cells (Fig 5). Hereafter, we describe the
transcriptional and metabolic changes directly due to SBDS deficiency, i.e. fully rescued by
SBDS readministration in the SbdsR126T/R126T background. To simplify, 527 genes were at least
2-fold altered at the transcriptional level in SbdsMOCK cells, all of them presenting concomitant
changes in the polysomal pool. Functional analysis by classical Gene Ontology (GO) for the
Molecular Function Domain was performed on these 527 genes. Twentyseven ontology terms
grouped in ten emerging categories were found as significantly enriched. Gene Set Association
Analysis (GSAA) on both polysomal and total fractions confirmed the findings of the classical
(GO) gene ontology (S3 File). Globally, we found that SBDS mutant cells had a decrease in
genes encoding for the ribosomal and respiratory chains, and an increase in the lysosomal
capability. We will specifically describe some of them. We found upregulated (both at the poly-
somes and at the steady-state level) mRNAs with peptidase activity including lysosomal
cathepsins such as Ctsb, Ctsd, Ctsk and Ctsl (Fig 5A), and lysosomal genes with vacuolar
ATPase activity, including Atp6ap1, Atp6ap2 and Atpv0b (Fig 5A, S1 File). Validation was con-
firmed by quantitative PCR (Fig 5B). M6pr, Lamp1 and Atp6ap1 upregulation suggests
increased lysosomal activity associated with Sbds mutation, whereas increased CtsB suggests
higher degradation activity. Consistently, we found in SbdsMOCK cells an increase in cell acidifi-
cation by the Lysotracker assay (Fig 5C) and an increase in Lamp1 positive cells by immuno-
fluorescence (Fig 5D and 5E) and by western blot (S5A Fig). Other coordinated gene
expression changes observed in SbdsMOCK cells were a puzzling upregulation of membrane
transporters for aminoacids and other intermediates (S4A Fig), a downregulation in most
ribosomal components (S4B Fig), and a drop of expression of several genes important for
mitochondrial function (S1 and S2 Files). These findings, in line with a reduction in the global
protein synthesis capability observed in Fig 2G and 2H and in Fig 3, further predicted that
SbdsR126T/R126T cells might have a decrease in the level of high energy molecules like ATP.
Therefore, we measured intracellular ATP levels and found a decrease in ATP levels both in
SbdsR126T/R126T and SbdsMOCK cells respect to their controls (Fig 5F). The reduction of ATP lev-
els was also confirmed in HEK cells carrying an shRNA for SBDS (S5B and S5C Fig). In addi-
tion, we did not observe any significant difference 1. AMPK and 2. phospoAMPK levels,
whereas a mild difference was appreciate in 3. PhosphoAMPK substrates by western blots
(S5D and S5E Fig). We then measured the levels of secreted lactate and pyruvate (S6A and S6B
Fig), as index of the glycolytic flux, and we found a reduction in the Lactate/Pyruvate ratio
both in SbdsR126T/R126T and SbdsMOCK respect to their controls (Fig 5G). To further understand
the metabolism of these cells we measured the levels of a. glycolytic activity, b. respiration and
c. ROS production. We found that both SbdsR126T/R126T and SbdsMOCK cells show a decrease in
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glycolysis (S6C Fig) and a reduction in respiration (S6D Fig), while ROS levels remained
unchanged (S6E Fig). In conclusion, we demonstrate that the reduction of SBDS activity
causes a reduction of a global translational capability and a cellular adaptation with less energy
production and more compensatory catabolic capability.
We focused our attention on information deriving from LINCS/CMap project to evaluate if
the gene expression profile found altered in the total fraction of SbdsR126T/R126T MEFs cells was
similar to transcriptional changes induced by drugs, observed in other cell types and to eIF6
deficiency [41]. Analysis performed by Query web tool on the complete list of modulated
Fig 5. SBDS mutation results in increased lysomome trafficking and activity, and a decrease in ATP
and lactate levels predicted by changes in the steady-state of the mRNAs identified by RNA-seq. (A)
Changes in the steady-state levels (total, bona fide for transcriptional) of genes with peptidase activity as
detected both on polysomes and total. Heat maps representing absolute gene expression levels in SbdsMOCK
and SbdsRESCUE samples for the subset of gene sets with peptidase activity by Gene Ontology analysis. (B)
qPCR validation of selected genes associated to lysosome activity. Real time analysis of selected genes
associated to lysosome trafficking and activity. Data shown for n3; mean±s.d., T-test, paired, two-tailed. (C)
SbdsMOCK cells have a decrease in intracellular pH value. Representative graph showing increased
lysotracker fluorescence intensitity in SbdsMOCK cells respect to SbdsRESCUE cells. This result suggests more
lysosome trafficking and activity in SbdsR126T/R126T cells. Data shown for n3; mean±s.d., T-test, paired, two-
tailed. (D-E). Lamp1 immunostaining (representative cells, D) and quantitation (E). Scale bar indicates 8.3μm.
Globally, A-E show increase in the proteolitic potential of SbdsMOCK respect to SbdsRESCUE cells. (F-G) SBDS
levels positively regulate ATP accumulation (F) and lactate/pyruvate production, an index of glycolysis (G). All
graphs represent mean ± s.d. Statistic applied was T-test, paired, two-tailed, n4.
doi:10.1371/journal.pgen.1006552.g005
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genes, and on a subset of the most changed ones identifies three common PKC activators:
ingenol, phorbol-12-myristate-13-acetate and prostratin (S3 File).
SbdsR126T/R126T cells display a modest drug signature predicting stress
sensitivity
Overall the analysis on SBDS deficient cells suggests that they have an impaired translational
capability that leads to a compensatory transcriptional and metabolic rewiring that favors a
catabolic processes and a state of low energy versus high synthetic capability. We reasoned that
the transcriptional signature generated by SBDS deficiency could lead to a differential sensitiv-
ity to drugs or stressors which may be exploited at a therapeutic level. In principle, inhibitors
that preferentially repress the growth of SbdsR126T/R126T immortalized MEFs may be of use in
treating SDS patients who are affected by Acute Myeloid Leukemia (AML). On the contrary,
selective stimulators of growth could be potentially interesting for early-phase of the disease,
for instance in the context of neutropenia or pancreatic insufficiency. We decided to proceed
with two different screenings, the first based on 100 compounds selected from commercial
oral drugs (S4 File). We evaluated the response signature to drugs associated to R126T muta-
tion by measuring cell viability after 48h of treatment. We found that overall SbdsR126T/R126T
MEFs were similar to SbdsMOCK, and wt to SbdsRESCUE. This said, the signature profile that we
found was surprisingly similar between wt and SBDS deficient cells (Fig 6A), with only one
exception. In particular, we found increased sensitivity of SbdsR126T/R126T and SbdsMOCK cells to
chlorambucil (Fig 6B), a DNA alkylating agent. Microtubule-targeting drugs mebendazole and
colchicine were more toxic to SbdsR126T/R126T cells (S7 Fig), instead niclosamide had a stimula-
tory effect on SbdsR126T/R126T cells (S7 Fig), but the effects were not rescued in the SbdsRESCUE,
Fig 6. Drugs show a similar sensitivity profile between SBDS mutant or wt cells, but unveil a slight
sensibility to selective DNA damage in SBDS mutant cells. (A) 100 molecules drug screening. Wild type,
SbdsR126T/R126T, SbdsRESCUE and SbdsMOCK MEFs were treated for 48h with 100 molecules selected from
oral commercial drugs in UK. The heatmap shows a similar trend in all genotypes. However, the hierarchical
clustering underlies that SbdsR126T/R126T and SbdsMOCK cells are more similar among them, than the wild type
and SbdsRESCUE cells. (B) Dose-response sensitivity to Chlorambucil a DNA alkylating drug. After the first
large screening, molecules showing different activity in SbdsR126T/R126T were selected for a second dose-
response assay. The chemotherapic Chlorambucil is more toxic to SbdsR126T/R126T and SbdsMOCK MEFs
(1,6 μM and 3,2 μM, 48h). Two-tailed t-test, paired (***P value P0.001).
doi:10.1371/journal.pgen.1006552.g006
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suggesting indirect effects. The second screening with a Prestwick Library including 1280
compounds aimed at finding growth stimulators identified clindamycin (S7B Fig), but the
effect was not rescued in SbdsRESCUE cells. In conclusion, 1. Sbds mutation cause limited effects
unless cells are challenged, 2. chlorambucil data predict that SbdsR126T/R126T cells might be
more sensitive to stress causing DNA damage.
The increased toxicity of the alkylating agent chlorambucil in SbdsR126T7R126T cells hinted a
possible increased susceptibility to cell death associated to other forms of DNA damage. We
first measured the basal level of apoptosis in wild type and in SbdsR126T/R126T cells by measuring
the AnnexinV/7AAD positive population, and we did not find any differences between the
two genotypes (Fig 7A). Treatment of cells with UV pulses caused an increase in cell death
(Fig 7A), that was significantly more marked in SbdsR126T/R126T and in SbdsMOCK respect to
wild type or SbdsRESCUE cells (Fig 7B). We analyzed DNA damage by examining cells with the
COMET assay (Fig 7C and 7D), where the tail moment revealed a slight but significant
increase in DNA damage in SbdsMOCK respect to wild type or SbdsRESCUE cells. This effect, even
if small, is consistent with increased sensitivity of SbdsMOCK to two external stresses acting on
DNA like chlorambucil and UV rays. These data, together with a decrease in energy levels and
the uncapability to grow in vivo, show that Sbds mutated cells have an intrinsic fragility, that
makes them weaker respect to their wild type counterpart.
Discussion
Our study suggests a model (Fig 8A) that may explain the pathogenic culprit of SDS and will
be first described. The table in Fig 8B outlines the phenotypes that we have observed.
A simple model for SBDS-driven pathological symptoms is based on a threshold concept.
Total null SBDS mutations are never observed in humans indicating that a zero threshold of
Fig 7. SbdsR126T/R126T and SbdsMOCK cells show an increase in cell death in response to UV stress.
(A-B) UV exposure damages more SBDS mutant cells than wt or SbdsRESCUE. (A) Experiment on
SbdsR126T/R126T versus wt. There is an increase in cell death in SbdsR126T/R126T versus wild type cells. In
basal conditions no differences are observed among the genotypes (first two bar triplets, left). Upon UV
damage cell death affects more SbdsR126T/R126T (second two bar triplets, right). Cells were stressed with UV
irradiation (9999 μJ/cm2, three times), recovered for 4 hours and stained for annexin with 7-AAD. (B)
Observed ratios in all genotypes. Ratio 1 indicates higher sensitivity, the rescue with SBDS only partly
restores the ratios. (C-D) COMET assay. Representative images of indicated cells treated as indicated in
manufacturer protocol (Comet assay kit, Trevigen) in (C). Scale bars indicate 20 μm. (D) Absolute quantitation
of the tail moment unveils a minor but significative difference.
doi:10.1371/journal.pgen.1006552.g007
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SBDS is incompatible with life. Mutant SBDS has a residual activity. This activity is sufficient
for, i.e., normal proliferation, but becomes limiting for efficient colony formation or escaping
senescence. If senescence is bypassed by oncogene-driven immortalization and transforma-
tion, then, SBDS remains still limiting for survival in nude mice. We can therefore imagine
that each individual cell, in each moment, may or may not meet the condition of insufficient
Fig 8. Model for SBDS-induced changes. (A-B) We speculate that SBDS mutation poises cells at a low
energy level due to impaired global translation. Cells have a complex transcriptional rewiring and adapt by
increasing the proteolytic flux. In this condition, they are less responsive to growth stimuli (example Fig 1), but
more sensitive to stressors respect to wt cells. Interventions to increase translational efficiency are predicted
to increase their fitness. (B) Summar table indicating all phenotypes observed in this study in Sbds mutant
cells.
doi:10.1371/journal.pgen.1006552.g008
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SBDS activity, with subsequent effects. Indeed, by the SUnSET protocol we see that only some
SBDS mutant cells do not reach high translation levels.
If the threshold is not reached, our study supports a model in which SBDS deficiency leads
primarily to a delayed maturation of 60S ribosomal subunits. We confirm that the number of
eIF6 binding sites on 60S ribosomes is reduced, consistent with reduced generation of free 60S
and with a proposed model of SBDS-mediated eIF6 release in the late maturation of 60S, in
cooperation with EFL1 [26]. In detail, we quantify a 25% decrease of eIF6 binding sites on 60S,
similar to [42]. We also report that the increase of free 60S is 2-fold, the amount of accumulated
ACA8/ACA31 snoRNAs on immature 60S is 4-fold, and ribosomal extracts from SBDS mutants
have a 70% reduction in translational capability. Apparently, the ribosomal deficit due to SBDS
mutation is more pervasive than expected and suggests the generation of a bulk of immature 60S
that are poorly active in translation, even if eIF6 is released. This said, eIF6 release may be critical
in the rescue of some mature ribosomes and the alleviation of pathological consequences.
A variety of proxyes due to reduced SBDS activity are evident. Indeed, adaptation is evident
in the absence of overt signs of SBDS insufficiency. Even if SBDS mutant cells proliferate nor-
mally in rich media, they show a signature with reduced energy level, increased lysosomal capa-
bility, decreased ribosomal production and less oxygen consumption. The drug screening
identified a subtle signature of fragility which may contribute to the pathology. Previously, it was
reported excess protease secretion in SDS-derived iPSC [43], reduced respiration in yeasts and
mammalian cell models [34], and less ATP [35] that together with our extended gene signature
define a status of reduced anabolic capability. This may be a keyfactor for rescuing the pheno-
type. Stimulators of ATP production, for instance, may have an impact on the disease. Our initial
drug screening suggests that efforts in this direction may be valuable: we screened drugs for sur-
vival activity and found that SBDS mutants are remarkably similar to wt cells. However, a screen-
ing for a closer proxy of SBDS deficiency such as ATP levels, may lead to successful compounds.
We think that increased AML in SDS patients is a defect due to impaired host-cancer inter-
play, rather than due to genetic instability. If anything, SBDS-deficient cells are very resistant
to oncogenic transformation and unable to grow in unfavourable conditions like the ones gen-
erated in tumors (see xenografts). In the bone marrow of SDS models, the neutrophil lineage
can be impaired by the absence of sufficient endogenous SBDS activity [9]. SDS patients have
neutropenia [44]. It is known that severe congenital neutropenia is associated with the pro-
gression to acute myeloid leukemia [45]. Therefore, we speculate that neutropenia in the bone
marrow niche [30, 42] may lead to expansion of tumor cells that cannot be eliminated by
proper immunosurveillance. Similar suggestions came from mouse work [46]. In summary,
for therapy, we need to address which cell is directly affected by SBDS deficiency.
A divergence between our studies and previously published works relates to ROS [28] pro-
duction. In our hands we did not find evidence for increased ROS production. It is possible
that impaired ROS balance is observed as an indirect effect driven by mitochondrial alterations
in specific cells, but is not a direct proxy of SBDS deficiency.
Finally, we would like to comment on translational control driven by SBDS and eIF6. SBDS
insufficiency generates a unique phenotype. Similarly to SBDS mutants, eIF6 depletion pro-
tects from oncogene-induced transformation [25, 47], whereas its amplification is oncogenic
[48, 49]. eIF6 depletion does not induce senescence [25], but induces a different transcriptional
rewiring [41], a divergent bone marrow phenotype affecting platelets [50], and a generally
improved metabolic status [41]. SBDS depletion reduces the translation of mRNAs undergoing
reinitiation, as CEBP/β derived LIP peptide [26]. In our study the decrease of CEBP/β mRNA
on polysomes driven by SBDS deficiency is around 10% (S1 Table). eIF6 depletion reduces
both reinitiation and LIP expression as well as the translation of G/C rich mRNAs [41]. To
summarize, the specific effects of eIF6 loss and SBDS loss are different, but overall they suggest
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that both eIF6 and SBDS have a stimulatory role in protein synthesis. In yeast and Dictyoste-
lium eIF6 mutants revert the SBDS loss [19, 20, 22]. We speculate that these mutants are gain-
of-function genes and that eIF6 agonists may be beneficial to the disease.
In conclusion, our results support the idea that cells with reduced SBDS activity are able to
grow and cycle as well as wild type cells in proper conditions, but if they drop below a SBDS
threshold level they show a phenotype. However, the adaptation signature suggests logical
roads for improving their fitness. In the long run a screening for compounds which may accel-
erate the release of eIF6 from 60S subunits can be helpful to discover specific drugs for treating
SDS (assuming that a modest increase in active 60S can strongly ameliorate the phenotype).
Alternatively, screening on proxyes such as ATP levels may lead to faster therapeutic options.
Materials and Methods
Cell culture and infections
Primary wild type and SbdsR126T/R126T MEFs (E12.5) were grown in DMEM (Lonza), supple-
mented with 10% Fetal Bovine Serum (FBS) and 1% penicillin, streptomycin, L-glutamine,
and maintained at 37˚C and 9% CO2. Mycoplasma testing was performed before experiments.
These cells were infected at early passages through retroviral vectors carrying DNp53 + onco-
genic H-rasV12 [25]. After immortalization, cells were maintained at 37˚C and 5% CO2.
Immortalized SbdsR126T/R126T MEFs were infected with lentiviral vectors carrying the wild type
Sbds to generate the SbdsRESCUE line or with the corresponding empty vector to obtain the
SbdsMOCK line. The lentiviral vectors (pHAGE-CMV-dsREDexpressIRESzsGreen backbone
vectors) used to reconstitute SBDS wild type protein were kindly provided by A. Shimamura
(Fred Hutchinson Cancer Research Center, Seattle). HEK-293T and HeLa cells from ATCC
were cultured in DMEM (Euroclone) supplemented with 10% FBS and penicillin/streptomy-
cin/glutamine solution (GIBCO) at 37˚C and 5% CO2. Mycoplasma testing was performed
before experiments. 293T cells were transfected at 60–70% confluence with pFCY, SBDS
shRNA and pFCY scramble lentiviral vector (a generous gift from the lab of DC. Link, Wash-
ington University School of Medicine) to produce lentiviral particles. HeLa cells were infected
with lentivirus at a confluence of 50%. Experiments were performed one week after infection.
Silencing of protein was measured by western blot analysis. All animal experiments were car-
ried out under the guidelines of the Canadian Council on Animal Care, with approval of pro-
cedures by The Animal Care Committee of the Toronto Centre for Phenogenomics, Toronto,
AUP #0093.
Transformation assay, soft agar and in vivo tumor growth
For the transformation analysis, primary fibroblasts were infected at early passage with DNp53
+ H-rasV12 retroviral vectors and left to grow at overconfluency. Foci were counted 3 weeks
after infection and cells were recovered for in vivo experiments. Eight-weeks old CD1 athymic
nude mice were used for detecting tumor growth after a subcutaneous injection of in vitro
transformed MEFs (500,000 cells/mouse). Tumor growth was monitored and animals were
euthanized when the tumor reached the size of 400 mm3. All experiments involving mice were
performed in accordance with Italian National Regulations. Experimental protocols were
reviewed by local Institutional Animal Care and Use Committees. The soft agar formation
assay and the focus formation assay were performed as described previously [51]. In vitro
assays were performed at least three times, each in triplicate.
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Polysome profiles
Growing cells were lysed in 50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 30 mM MgCl2, 0.1%
Nonidet P-40, 100 μg/ml cycloheximide and 40 U/mL RNasin. After centrifugation at 12,000 r.
p.m. for 10 min at 4˚C, cytoplasmic extracts with equal amounts of RNA (10 OD260) were
loaded on a 15–50% (or 10–30%) sucrose gradient dissolved in 50 mM NH4Cl, 50 mM Tris-
Acetate, 12 mM MgCl2, 1 mM DTT and centrifuged at 4˚C in a SW41Ti Beckman rotor for 3
h 30 min at 39,000 r.p.m. Absorbance at 254 nm was recorded by BioLogic LP software
(BioRad) and fractions (1.5 mL each) were collected for subsequent proteins or RNA extrac-
tion. Each experiment has been performed at least six times, for each condition.
RNA isolation and RNA sequencing and quantitative PCR
Total RNA was extracted from sucrose gradient aliquots. For the 15–50% gradient, we pulled
fractions corresponding to polysomes in one fraction, and we pulled 100 μL from each fraction
from the whole gradient in one fraction (total). For the 10–30% gradient, we pulled fractions
corresponding only to the 80S peak in one fraction, named 80S, and we used as total RNA ali-
quots from the pre-gradient loading extract (pre-load). Afterward, we added to samples pro-
teinase K (to a final concentration 100μg/mL) and SDS (to a final concentration of 1%) and we
incubated them for 1 h at 37˚C. Total RNA was then extracted by phenol/chloroform/isoamyi-
lic acid method (https://tools.thermofisher.com/content/sfs/manuals/trizol_reagent.pdf).
Libraries for Illumina sequencing were constructed from 100 ng of total RNA with the Illu-
mina TruSeq RNA Sample Preparation Kit. The generated libraries were loaded on to the cBot
(Illumina) for clustering on a HiSeq Flow Cell v3. The flow cell was then sequenced using a
HiScanSQ (Illumina). A paired-end (2×101) run was performed using the SBS Kit v3 (Illu-
mina). Experiments were performed in biological triplicates.
For quantitative PCR, 150 ng of RNA was retrotranscribed according to SuperScriptTM III
First-Strand Synthesis SuperMix manufacturer protocol (18080400, Life Technologies).
For RNASeq validation, Taqman probes specific for Atp6ap1 (Mm01187488_g1), Lamp1
(Mm00495262_m1), Ctsb (Mm01310506_m1) and M6pr (Mm04208409_gH) were used. Tar-
get mRNA quantification was performed by using ΔCt-method with 18S rRNA as an internal
standard, performed on a StepOne Puls System (Applied Biosystems). Results are represented
as means + s.d. of three independent experiments.
Bioinformatics analysis
Read pre-processing and mapping. Three biological replicates were analyzed for polyso-
mal, total and 80S fractions, with the exception of 80S SbdsRESCUE condition, for which two
biological replicates were available. Three replicates were examined for pre-load samples. Raw
reads were checked for quality by FastQC software (version 0.11.2) (Available from: http://
www.bioinformatics.babraham.ac.uk/projects/fastqc), and filtered to remove low quality calls
by Trimmomatic (version 0.32) [52] using default parameters and specifying a minimum
length of 50. Processed reads were then aligned to mouse genome assembly GRCm38
(Ensembl version 77) with STAR software (version 2.3.0e) [53].
Gene expression quantification and differential expression analysis. HTSeq-count
algorithm (version 0.6.1, options = no, gene annotation release 77 from Ensembl) [54] was
employed to produce read counts for each sample. To estimate differential expression, the
matrix of read counts produced by HTSeq was analyzed by DESeq2 (version DESeq2_1.6.3)
[55]. In a first step, differential expression analysis by DeSeq2 algorithm was performed to
compare SbdsMOCK versus SbdsRESCUE genotypes in polysomal or in total fractions (12 samples
overall). Read counts were normalized by calculating a size factor, as implemented in DESeq2.
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Independent filtering procedure was then applied, setting the threshold to the 65 percentile;
14471 genes were therefore tested for differential expression. Significantly modulated genes in
polysomal or total fractions were selected by considering an absolute value of log2 fold change
higher than 1 and a false discovery rate lower than 5%. In the same analysis framework, the
moderate fold-change (as implemented by DeSeq2) was calculated for the polysomal versus
the total fraction in SbdsMOCK as well as SbdsRESCUE conditions and considered as measure of
the translational efficiency. The comparison between the two genotypes was obtained by calcu-
lating a delta Log2 fold-change between SbdsMOCK and SbdsRESCUE and visually represented by
a histogram.
Regularized logarithmic (rlog) transformed values were employed for heat map representa-
tion of gene expression profiles.
Similarly, DESeq2 workflow was applied for the comparison of SbdsMOCK versus SbdsRESCUE
in the 80S fraction (5 samples). Independent filtering threshold of 65% resulted in the selection
of 14484 genes for statistical testing. In order to compare the levels of 80S and pre-load,
DESeq2 normalization and regularized log transformation steps were performed on the sam-
ples belonging to these experimental conditions together, and the genes of interest were visual-
ized by a heat map.
Analyses were performed in R version 3.1.2 (2014-10-31) (R Core Team (2015). R: A lan-
guage and environment for statistical computing. R Foundation for Statistical Computing,
Vienna, Austria. URL https://www.R-project.org/.).
Functional analysis by ClueGO. Cytoscape plug-in ClueGO (version 2.2.3) [56] was
employed to perform gene ontology analysis and generate enrichment networks on the pool of
527 genes selected as modulated both in the polysomal and in the total fractions, using the
group of 14471 tested genes as custom reference set. The Molecular Function domain of the
Gene Ontology was considered. The following parameters were set: level 3–8, k = 0.4, Min
Number of Genes = 8, Min Percentage = 8%, Pval < 0.01 (Enrichment; Bonferroni Step
down).
Gene set association analysis
Gene set association analysis for polysomal and total fractions was performed by GSAA soft-
ware (version 1.2) [57]. Raw reads for about ~ 22000 genes identified by Entrez Gene ID were
analyzed by GSAASeqSP, using gene set C5 (mouse version retrieved from http://bioinf.wehi.
edu.au/software/MSigDB) and specifying as permutation type ‘gene set’ and as gene set size fil-
tering min 15 and max 800.
CMap analysis
Analysis on CMap/LINCS gene signatures was performed using the ‘Query’ web tool (http://
apps.lincscloud.org/query), that, taking as input a list of genes, computes the connectivity
between this set and the gene expression signatures of the LINCS database. Human orthologs
of mouse genes were retrieved relying on Biomart web tool (http://www.ensembl.org/
biomart); only genes with a one-to-one orthologs relationship were maintained for down-
stream computations. Query tool was first applied on the list of 726 mouse genes significantly
modulated in the total fraction; chemical compounds showing a mean rank value of at least 90
on 6 cell lines were selected as interesting. As second strategy, the same procedure was applied
on the genes showing a robust modulation (143 genes with a fold-change higher than 3 as
absolute value) and then selecting chemical compounds with a mean rank value of at least 90
on 4 cell lines. To find perturbations that are consistently retrieved, the overlap between the
two analyses was considered as final result.
Direct Effects of SBDS Deficiency
PLOS Genetics | DOI:10.1371/journal.pgen.1006552 January 5, 2017 17 / 26
Western blotting and antibodies
SDS-PAGEs were performed on protein extracts obtained with RIPA buffer (10 mM Tris-HCl,
pH 7.4, 1% sodium deoxycholate, 1% TritonX-100, 0.1% SDS, 150 mM NaCl and 1 mM
EDTA, pH 8.0). Protein concentration was determined with BCA analysis (Thermo Fisher
Scientific). Equal amounts of proteins were loaded on each lane and separated on a 10%
SDS-PAGE, then transferred on a PVDF membrane. The membranes were blocked in 10%
Bovine Serum Albumin (BSA) in Phosphate Buffer Saline (Na2HPO4 10 mM, KH2PO4 1.8
mM, NaCl 137 mM, KCl 2.7 mM, pH 7.4) (PBS) with Tween (0,01%) for 30 minutes at 37˚C.
The following primary antibodies were used: β-actin (CST 4967L 1:4000), SBDS (Santa Cruz
S15 SC49257 1:500) H-RAS (Santa Cruz SC520, 1:1000), Lamp1 (Santa Cruz SC20011, 1:200),
AMPK (CST 5831 1:1000), phospho-AMPK (CST 2535 1:1000), phospho-AMPK Substrates
(CST 5759, 1:1000). The following secondary antibodies were used: donkey anti-goat IgG HRP
(Santa Cruz SC2020, 1:2000), donkey anti-rabbit IgG HRP (Amersham NA934 1:5000) and
donkey anti-mouse IgG HRP (Santa Cruz, SC2005 1:5000). Each experiment was performed at
least three times, each time in triplicate.
Immunofluorescences and antibodies
Cells were seeded the day before the staining. The next day, cells were rinsed three times with
PBS then fixed with ice cold methanol 100% for 10 minutes at -20˚C. After three washes with
PBS, cells were blocked in Normal Goat Serum 5%, for 1 hour at room temperature. Primary
antibodies were incubated overnight at 4˚C, and after three washes with PBS, secondary anti-
bodies were incubated 3h at room temperature in the dark. After three washes with PBS, cells
were incubated with DAPI (Molecular Probes NucBlue Live ReadyProbes Reagent R37605) as
manufacturer protocol, then washed and mounted on slides with Mowiol 20%. All the anti-
bodies were diluted in blocking solution. The following primary antibodies were used: NPM
[25], SBDS (Santa Cruz S15 SC49257 1:25), eIF6 [58] (1:100), Lamp1 (Santa Cruz sc-20011
1:100). The following secondary antibodies were used: donkey anti-goat, donkey anti-mouse,
donkey anti-rabbit (Alexa Fluor secondary antibodies, Molecular Probes 1:500). The cells were
examined by confocal microscopy (Leica SP5) and analyzed with Volocity 6.3 software (Perkin
Elmer). Immunofluorescence experiments were performed at least three times, in triplicate.
Comet assay
Comet assay was performed following the manufacturer protocol (Trevigen, 4250-050-K). The
stained nuclei were then examined by confocal microscopy (Leica SP-5), and analyzed (n30
for each condition) with Comet Assay IV software (Perceptive Instruments). The experiment
was performed three times in triplicate.
Ribosome biogenesis
Ribosome biogenesis was analyzed by pulse-chase experiments by adding 5,6-3H-Uridine to
the medium (final concentration 3uCi/mL, NET367001MC PerkinElmer). 5,6-3H -Uridine
was removed after 0, 10, 20 and 40 minutes of incubation and RNA was extracted with Trizol
Reagent and hybridized on nitrocellulose membrane. This experiment was reproduced twice.
In vitro translation assay
For in vitro translation assays, we used cell extracts prepared as described [59] with some opti-
mizations. 80% confluent cells were trypsinized and lysed for 45 minutes at 4˚C in 10 mM
HEPES pH 7.6, 10 mM potassium acetate, 0.5 mM magnesium acetate, 5 mM DTT and
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protease inhibitor (Promega). Lysates were homogenized by syringing through a 27G, 3/
4-inch needle. Lysates were clarified by centrifugation at 18.000 g for 1 minute and protein
concentration was determined by BCA quantification assay. To make translation fully depen-
dent on exogenously added mRNA, lysates were treated with 15 U/ml Micrococcal nuclease
(MN Boehringer) and 0.75 mM CaCl2 and incubated at 25˚C for 7 minutes. EGTA was added
to terminate the reaction.
For the translation assay, 6 μl of cell extract were mixed to 1.2 μl of Master Mix (125 mM
HEPES, 10 mM ATP, 2 mM GTP, 200 mM creatine phosphate, 0.2 mM aminoacid mix with-
out methionine (Promega), 0.25 mM spermidine, 20 mM of L-methionine, 50 mM potassium
acetate, 2.5 mM magnesium acetate, 20 U of RNAsin (from Promega) and 0.5 μg of purified
reporter-encoding mRNA). The mRNA was obtained by using the Megascript T7 kit
(Ambion) to perform the in vitro transcription reaction supplemented with 2 mM cap analog
[M7G(5’)PPP(5’)G] (Ambion). The mix for the in vitro translation reaction was then incu-
bated for 90 minutes at 30˚C. Dual-Glo Luciferase Assay kit (Promega) was used to read Firefly
and Renilla luciferase output with GloMax Luminometer (Promega). In vitro translation
experiments were performed at least three times, in triplicate.
SUnSET assay
For protein synthesis measurements, we adapted SUnSET protocol [60]. 70% confluent cells
were treated with 5μg/ml puromycin for 10 minutes, then trypsinized and centrifugated 5 min-
utes at 500 g. Then, cell were fixed and permeabilized using reagents from the Foxp3/Tran-
scription Factor Staining Buffer Set (Affymetrix, 5523–00), incubated with anti-puromycin
12D10 (1:2000, Millipore, MABE343) and finally with secondary antibody Alexa Fluor 488
Goat anti-Mouse (Invitrogen) and DAPI, according to manufacturer protocol. Cells were then
analyzed with FACSCanto II (BD Bioscience) and analyzed with FlowJo8.8.7 software. SUn-
SET experiments were performed at least three times, in triplicate.
Drug screenings
100 molecules screening. Cells were plated in 96 well (6000 cells/well) 4 hours before
drug treatments. The list of all drugs with their relative concentration is in the S4 File. Unless
specified, the drug treatment time is 48 hours. Cell viability was measured with Cell Titer Blue
(Promega, G8080), according to the manufacturer’s protocol. All treatments were performed
at least three times, in triplicate.
FDA screening
1280 approved drugs were analyzed for their impact on SbdsR126T/R126T cells growth. Cells
were seeded using a Multidrop Combi (Thermo Scientific) in 384 well plates (Perkin Elmer
Cell Carrier, collagen coated) at a density of 4000 cells/well. After 24 hours the drugs were sup-
plemented using a Hamilton Starlet liquid handler at a final concentration of 10 μM and cells
were treated for 30 hours. The reference compound for toxicity was 5 μM Trichostatin A.
Cytotoxicity was than evaluated by measuring in vivo nuclear shrinkage and loss of cells using
Hoechst33342, and cell membrane disruption using the cell-impermeant nuclear dye BOBO-
3. Briefly, following incubation with the drugs diluted in 50 μl growth medium, 25 μl of a dye
cocktail containing 3 μM Hoechst33342 and 2.25 μM BOBO-3 were added and incubation was
continued for further 45 min at 37˚C, 5% CO2. Images were then immediately acquired and
analyzed using the Operetta microscope (Perkin Elmer). For the validation of hits, 6-point
dose-responses for each compound in duplicate were used (ranging from 30uM to 0.12uM).
The number of dead cells/total number of cells was the readout of the assay, where dead cells
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correspond to nuclei stained with BOBO-3 and the total number of cells correspond to the
nuclei stained with Hoechst33342.
Metabolism analysis
Secreted lactate. Cells were plated in 6 well dishes in high-glucose medium for 24 hr
and then switched to serum-free high-glucose (4,5 g/L) for 4 hr as indicated in [61]. Lactate
secreted into the medium was measured using a fluorogenic assay, Lactate Assay Kit (Biovi-
sion). Average of fluorescence intensity was calculated for each condition replicates. Values
were normalized to protein content obtained from the same wells.
ATP levels. For ATP measurements, samples were homogenized in ice-cold ATP buffer
(20 mM Tris, pH 7.5, 0.5% Nonidet P-40, 25 mM NaCl, 2.5 mM EDTA) for 5 min. Lysates
were centrifuged at 13,000 g for 30 min. Proteins were quantified by BCA analysis. Lumino-
metric determination of ATP was assayed using the ATP-determination kit (Molecular
Probes) according to [62].
Glycolysis and extracellular O2 consumption assays. For respiration and glycolysis anal-
ysis, fluorogenic kits were used (respectively, Abcam ab197243 and ab197244), following man-
ufacturer protocols. Average of fluorescence intensity was calculated for each replicate, and
then values were normalized for cells number.
Pyruvate levels. For pyruvate analysis, a fluorimetric kit was used (BioVision, K609-100)
following manufacturer protocol. Average of fluorescence intensity was calculated for each
replicate, and then values were normalized for protein content obtained. All assays were per-
formed at least three times, in triplicates.
Cell death and ROS production measurement
All analysis were performed using the FACSCanto II Flow cytometer (BD) and analyzed with
FlowJo software (BD). All experiments were performed when cells reached the confluence of
70%. For the apoptosis analysis, cells were UV irradiated with a cross-linker (9999 μJ/cm2,
three times) and cell death was detected by using the 7AAD-Annexin V kit (640926, BioLe-
gend). For ROS measurement, cells were incubated with 50 μM H2DCF-DA (2’, 7’, -dichloro-
dihydrofluorescein diacetate, AbCam Ab113851) for 30 min at 37˚C and 5% CO2 and
immediately analyzed by flow citometry. All experiments were performed at least three times,
in triplicate.
In vitro ribosome interaction assay (iRIA)
iRIA assay was performed as described in [40]. Briefly, 96-well plates were coated with a cellu-
lar extract diluted in 50 μL of PBS, 0,01% Tween-20, O/N at 4˚C in humid chamber. Coating
solution was removed and aspecific sites were blocked with 10% BSA, dissolved in PBS, 0,01%
Tween-20 for 30 minutes at 37˚C. Plates were washed with 100 μl /well with PBS-Tween.
0,5 μg of recombinant biotynilated eIF6 was resuspended in a reaction mix: 2,5 ;mM MgCl2,
2% DMSO and PBS-0.01% Tween, to reach 50 ;μl of final volume/well, added to the well and
incubated with coated ribosomes for 1 hour at room temperature. To remove unbound pro-
teins, each well was washed 3 times with PBS, 0,01% Tween-20. HRP-conjugated streptavidine
was diluted 1:7000 in PBS, 0,01% Tween-20 and incubated in the well, 30 minutes at room
temperature, in a final volume of 50 μl. Excess of streptavidine was removed through three
washes with PBS-Tween. OPD (o-phenylenediamine dihydrochloride) was used according to
the manufacturer’s protocol (Sigma-Aldrich) as a soluble substrate for the detection of strepta-
vidine peroxidase activity. The signal was detected after the incubation, plates were read at 450
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nm on a multiwell plate reader (Microplate Bio-Rad model 680). This experiment was per-
formed at least three times, in triplicate.
Lysotracker assay
Cells were seeded the day before the assay. The next day, cells were incubated with Lysotracker
DeepRed (Thermo Fisher Scientific L12492) according to the manufacturer protocol. The cells
were examined with Nikon Ti-Eclipse microscope and analyzed with Volocity 6.3 software
(Perkin Elmer). For subsequent analysis, cells were then fixed with paraformaldehyde 3% for
10 minutes at room temperature and nuclei were stained with DAPI (Molecular Probes Nuc-
Blue Live ReadyProbes Reagent R37605) as manufacturer protocol, then washed and mounted
on slides with Mowiol 20%. The cells were examined by confocal microscopy (Leica SP5) and
analyzed with Volocity 6.3 software (Perkin Elmer). Lysotracker experiments were performed
at least three times, in triplicate.
Accession number
The RNA seq data are available at www.ebi.ac.uk/arrayexpress with accession number ID:
E-MTAB-5089.
Supporting Information
S1 Fig. Normal features of immortalized SbdsR126T/R126T MEFs. (A) Morphological appear-
ance of immortalized SbdsR126T/R126T MEFs. Representative phase-contrast picture of the
immortalized cell line obtained with DNp53 + H-rasV12 oncogenes infection. Scale bar indi-
cates 25 μm (B) Ras overexpression. Representative Western Blot of not-infected or DNp53
+ H-rasV12 infected cells indicating the overexpression of ras oncogene. The blot was per-
formed one week after the infection. (C) Doubling Time. Doubling time of multiple immortal-
ized WT and SbdsR126T/R126T MEFs. The doubling time was measured with a cell viability assay,
at three different time points (24h, 48h, 72h). (D) SBDS protein levels. Representative Western
Blot on wt, SbdsR126T/R126T, SbdsRESCUE and SbdsMOCK fibroblasts shows increased levels of
SBDS protein in SbdsRESCUE MEFs after infection with a lentiviral vector carrying the wild type
form of SBDS. The blot was performed one week after the infection.
(TIF)
S2 Fig. SbdsR126T/R126T mutation is not associated to alteration in rRNA precursor, but leads
to an impairment in CAP-dependent translation that is not rescued after the addition of
SBDS peptide. (A) Pulse and chase assay. Ribosomal RNAs precursors were analyzed with
5,63H-Uridine incorporation in SbdsR126T/R126T, SbdsRESCUE and SbdsMOCK MEFs at four differ-
ent time points (0, 10, 20 and 40 minutes of incubation with medium supplemented with 3 μCi/
mL 3H-Uridine). There are no differences among genotypes analyzed. (B) SBDS and eIF6 local-
ization. Confocal images on wild type and SbdsR126T/R126T cells indicate the same co-localization
of SBDS and eIF6 proteins within the nucleus. Scale bar 25 μm. (C) In Vitro Translation Assay.
Luciferase activity was measured as index of CAP-dependent translation efficiency and indi-
cates that SbdsR126T/R126T fibroblasts have less capability respect to wild type cells. No rescue has
been observed by adding the wild type SBDS protein. Graphs represent the mean of values,
error bars indicates standard deviation. Two-tailed t-test, paired (P value0.05, P0.001).
(TIF)
S3 Fig. Differentially expressed genes in polysome and in 80S fractions are mostly shared
by their total fractions. (A-B) Heat maps representing gene expression profile in polysomal
and total fractions (biological replicates) for the pool of 844 genes identified as significantly
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changed in polysomes (A) and in 80S (B) and pre-load samples for the pool of 250 genes
selected as significantly changed in 80S fraction. Values are represented as z-scores after rlog
transformation.
(TIF)
S4 Fig. Differentially expressed genes in total mRNAs. (A-B) Heat maps representing gene
expression profile of mRNAs from the solute carrier genes class (A) and for the structural con-
stituent of the ribosome (B). Values are represented as z-scores after rlog transformation.
(TIF)
S5 Fig. Lamp1, ATP and phosphoAMPK/AMPK/AMPK substrates levels. (A) Representa-
tive Western Blot showing increased levels of Lamp1 in SbdsMOCK cells respect to SbdsRESCUE
MEFs. (B) Representative Western Blot showing the levels of SBDS protein in HEK-293T
cells infected with the pFCY SBDS shRNA lentiviral vector (SBDS shRNA) or pFCY scramble
vector (scramble). (C) ATP levels in SBDS shRNA HEK-293T cells were reduced when com-
pared to control cells. Graphs represent the mean of values, error bars indicates standard devi-
ation. Two-tailed t-test, paired (P value0.05, P0.001). (D) Representative Western Blot
showing that wt, SbdsR126T/R126T, SbdsRESCUE and SbdsMOCK MEFs have the same levels of
AMPK and phosphoAMPK proteins. (E) Representative Western Blot showing that both
SbdsR126T/R126T and SbdsMOCK MEFs have a mild increase in phosphoAMPK substrates com-
pared to wild type and SbdsRESCUE cells.
(TIF)
S6 Fig. SBDS deficiency is associated to altered metabolism. SbdsR126T/R126T and SbdsMOCK
MEFs display a significant decrease in lactate (A) and pyruvate (B) levels, also confirmed by a
reduction in glycolytic activity (C), measured with extracellular pH levels, respect to their con-
trols wild type and SbdsRESCUE MEFs. SbdsR126T/R126T and SbdsMOCK MEFs display also a reduc-
tion in respiration (D), but ROS levels (E) remain unchanged. Graphs represent the mean of
values, error bars indicates standard deviation. Two-tailed t-test, paired (P value0.05,
P0.001).
(TIF)
S7 Fig. Differential sensitivity to drugs observed in the SbdsR126T/R126T versus wt, but not
recovered in the SbdsRESCUE. After the first large screening, molecules showing different
activity in SbdsR126T/R126T have been selected for a second dose-response assay including the
SbdsRESCUE. Four drugs confirmed the data on the parental cell lines but were not rescued, sug-
gesting clonal variations or indirect effects. (A) Niclosamide. (B) Clindamycin. (C) Mebenda-
zole. (D) Colchicine.
(TIF)
S1 File. Complete read counts of polysomal and total fraction. List of all genes detected and
tested for differential expression analysis in polysomal and total fraction for SbdsMOCK and
SbdsRESCUE. Gene quantification is calculated as normalized read counts.
(XLSX)
S2 File. Complete read counts of polysomal and total fraction. List of all genes detected and
tested for differential expression analysis in 80S fraction for SbdsMOCK and SbdsRESCUE. Gene
quantification is calculated as normalized read counts.
(XLSX)
S3 File. Functional analysis of translational and transcriptional changes associated to
R126T mutation. Gene Ontology annotation results; GSAA analysis on polysome and total
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fractions; LINCS/CMap analysis results.
(XLSX)
S4 File. 100 molecules drug screening. Concentration of 100 molecules used in the 100 mole-
cules drug screening with relative effects on all genotypes tested.
(XLSX)
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